Pantoprazole

• IUPAC: (RS ) -5 - ( difluoromethoxy ) -2 - [ (3,4- dimethoxy- 2-pyridyl) methylsulfinyl ] benzimidazole
• (±) -5 - ( difluoromethoxy ) -2 - [ (3,4- dimethoxy- 2-pyridyl) methylsulfinyl ] benzimidazole
• Latin: Pantoprazolum

• C16H15F2N3O4S ( pantoprazole )
• C16H14F2N3NaO4S ( pantoprazole sodium salt · )

A02BC02

Colorless crystalline powder ( pantoprazole sodium salt · )

Proton pump inhibitor Ulkustherapeutikum

An inhibitor of the proton- potassium pump

• 383.37 g · mol -1 ( pantoprazole )
• 405.35 g · mol -1 ( · pantoprazole sodium salt)

139-140 ° C ( pantoprazole )

Slightly soluble in ethanol, soluble in water, poorly in hexane

Sodium sesquihydrate ·

Attention

1000 mg · kg -1 ( LD50, Mouse, oral, sodium salt)

Template: Infobox chemical / molecular formula search available

Pantoprazole is a drug from the group of proton pump inhibitor that is used in the treatment of gastric and duodenal ulcers and in reflux oesophagitis.

• 2.1 Mechanism of action ( pharmacodynamics )

• 4.1 Chemical and pharmaceutical information 4.1.1 stereoisomerism

Clinical information

Indications / Applications

• Treatment and prophylaxis of peptic gastric and duodenal ulcers
• Reflux oesophagitis
• Eradication of Helicobacter pylori ( along with two appropriate antibiotics )
• Zollinger -Ellison syndrome

Pharmacological properties

Mechanism of action ( pharmacodynamics )

Pantoprazole exerts its effect in the parietal cells of the gastric mucosa, where it serves as an irreversible inhibitor of H / K -ATPase. This leads to a reduction of the hydrochloric acid production in the stomach, and the pH of the gastric juice increases. This leads to less aggressive gastric juice, which in turn favors the accelerated healing of gastric wall injury (eg, mucosal erosions, or ulcers ).

Side effects

Like the other proton pump inhibitor pantoprazole is also valid as a relatively safe and is largely well tolerated. Rare side effects include diarrhea, dizziness, fatigue and headaches. In comparison with omeprazole was a higher number of patients who experienced muscular pain was observed. Very rarely, thrombocytopenia are observed. Whether these are causally caused by the drug, has not been proven.

Other Information

Chemical and pharmaceutical information

Stereoisomerism

Pantoprazole has a chiral center at the sulfur atom, so it is chiral. The drug is a racemate, ie consists of a 1:1 mixture of ( R)-form and the mirror image ( S)-form.

History

Pantoprazole was in 1986 by Byk Gulden ( now Nycomed ) patented.

Veterinary medicine

In food-producing animals, the application is not allowed, since it is listed in any of the Annexes to Regulation (EEC ) No 2377/90 on maximum residue limits of veterinary medicinal products in foodstuffs.

Trade names

Azidex (A), Azidosan (A), Gastroloc (A), Gastrozol (D, A), Panprabene (A), Panprax (CH), Pantip (A), Pantoloc (A), Protonix (D, CH), Prazopant (A) Rifun (D), Zurcal (A, CH), Controloc ( PL ), numerous generics (D, A, CH) Protonix (USA)

ZacPac (D)